Effects of adjuvant chemotherapy on recurrence, survival, and quality of life in stage II colon cancer patients: a 24-month follow-up
- 459 Downloads
The purpose of this cohort study was to investigate the association of adjuvant chemotherapy with quality of life (QoL), survival, and recurrence over the 24 months following diagnosis in stage II colon cancer patients.
Overall, 453 patients were recruited from North Carolina from 2009 to 2011 and interviewed with a closed-ended survey detailing quality of life, health behaviors, treatment, and cancer recurrence at three times points: diagnosis, 12-, and 24-months post-diagnosis; mortality was obtained via the National Death Index.
In sum, 265 patients received chemotherapy. Receipt of chemotherapy exhibited an inverse association with total Functional Assessment of Cancer Treatment (FACT)-General (P < 0.01), FACT-Colorectal (P < 0.01), physical (P < 0.01), emotional (P = 0.02), and functional (P < 0.01) well-being; the inverse association between receiving chemotherapy and emotional well-being persisted for Caucasians but not African Americans (P interaction = 0.049). Those who received chemotherapy demonstrated significantly higher odds of cancer recurrence (odds ratio (OR) 2.74; 95 % confidence interval (CI) 1.18, 6.35) and all-cause mortality (OR: 1.95; 95 % CI: 1.05, 3.62).
In this study, stage II colon cancer patients who received chemotherapy treatment were more likely to have poor QoL, recurrence, and all-cause mortality after 24 months compared to those who did not receive chemotherapy. Future research focusing on subtypes of chemotherapy treatment, as well as a longer follow-up period, is needed.
KeywordsColon cancer Chemotherapy Quality of life Survival Recurrence
Quality of life
Functional assessment of cancer therapy-colorectal
Medical outcomes short form 12
Functional assessment of cancer therapy-general
Physical, social, emotional, and functional well-being
Colorectal cancer subscale
Trial outcome index-physical/functional/colorectal
Physical component score of SF-12
Mental component score of SF-12
This work was supported by a research grant from American Cancer Society (RSGT-08-094-CPPB).
The sponsors were not involved in the design of the study or in the data analyses or manuscript elaboration.
Conflict of interest
The authors declare that they have no competing interests.
- 1.Howlader N, Noone A, Krapcho M, Neyman N, Aminou R, Altekruse S, Kosary C, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner M, Lewis D, Chen H, Feuer E, Cronin K (2012) SEER cancer statistics review, 1975–2009. Nat Cancer Inst. http://seer.cancer.gov/csr/1975_2009_pops09/. Accessed February 13 2013
- 6.Allegra C, Yothers G, O’Connell M, Sharif S, Petrelli N, Colangelo L, Wolmark N (2011) Overall survival (OS) and updated disease-free survival (DFS) results of the NSABP C-08 trial assessing bevacizumab (B) in stage II and III colon cancer. In: J Clin Oncol (Meeting Abstracts) 15(suppl) 3508Google Scholar
- 7.Yothers G, Allegra C, O’Connell M, George T, Sharif S, Petrelli N, Lopa S, Wolmark N (2011) The efficacy of oxaliplatin (Ox) when added to 5-fluorouracil/leucovorin (FU/L) in stage II colon cancer. J Clin Oncol 29 (suppl):abstr 3507Google Scholar
- 11.Benson AB, Bekaii-Saab T, Chan E, Chen Y-J, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W, Sofocleous CT, Venook AP, Willett CG, Gregory KM, Freedman-Cass DA (2013) Metastatic colon cancer, version 3.2013: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw 11(2):141–152Google Scholar
- 12.Benson AB, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, Krzyzanowska MK, Maroun J, McAllister P, Van Cutsem E, Brouwers M, Charette M, Haller DG (2004) American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22(16):3408–3419. doi: 10.1200/jco.2004.05.063 CrossRefPubMedGoogle Scholar
- 14.Efficace F, Bottomley A, Coens C, Van Steen K, Conroy T, Schöffski P, Schmoll H, Van Cutsem E, Köhne C-H (2006) Does a patient’s self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer? Eur J Cancer 42(1):42–49CrossRefPubMedGoogle Scholar
- 16.Maione P, Perrone F, Gallo C, Manzione L, Piantedosi F, Barbera S, Cigolari S, Rosetti F, Piazza E, Robbiati SF (2005) Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced Non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. J Clin Oncol 23(28):6865–6872CrossRefPubMedGoogle Scholar
- 17.Eton DT, Fairclough DL, Cella D, Yount SE, Bonomi P, Johnson DH (2003) Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from eastern cooperative oncology group study 5592. J Clin Oncol 21(8):1536–1543CrossRefPubMedGoogle Scholar
- 23.Lynch HT, Lynch JF (2000) Hereditary nonpolyposis colorectal cancer. In: Seminars in surgical oncology. Wiley Online Library, 4:305–313Google Scholar
- 25.Howlader N, Noone A, Krapcho M, Garshell J, Neyman N, Altekruse S, Kosary C, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis D, Chen H, Feuer E, Cronin K (2013) SEER cancer statistics review, 1975–2010. National Cancer Institute, Bethesda http://seer.cancer.gov/csr/1975_2010/
- 27.Choi B (2003) Computer assisted telephone interviewing (CATI) for health surveys in public health surveillance: methodological issues and challenges ahead. Chronic Dis Can 25(2):21–27Google Scholar
- 33.Pischon T, Lahmann PH, Boeing H, Friedenreich C, Norat T, Tjønneland A, Halkjaer J, Overvad K, Clavel-Chapelon F, Boutron-Ruault M-C (2006) Body size and risk of colon and rectal cancer in the European prospective investigation into cancer and nutrition (EPIC). J Natl Cancer Inst 98(13):920–931CrossRefPubMedGoogle Scholar
- 39.NCI national cancer institute risk factor monitoring and methods branch, division of cancer control and population sciencesGoogle Scholar
- 41.Tofthagen C, Donovan KA, Morgan MA, Shibata D, Yeh Y (2013) Oxaliplatin-induced peripheral neuropathy’s effects on health-related quality of life of colorectal cancer survivors. Support Care Cancer:1–7Google Scholar
- 42.Douillard J, Cunningham D, Roth A, Navarro M, James R, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355(9209):1041–1047CrossRefPubMedGoogle Scholar
- 43.Borner M, Bernhard J, Dietrich D, Popescu R, Wernli M, Saletti P, Rauch D, Herrmann R, Koeberle D, Honegger H (2005) A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. Ann Oncol 16(2):282–288CrossRefPubMedGoogle Scholar
- 44.Heydarnejad M, Hassanpour DA, Solati DK (2012) Factors affecting quality of life in cancer patients undergoing chemotherapy. Afr Health Sci 11(2):266–270Google Scholar
- 45.Boyd KA, Briggs AH, Paul J, Iveson T, Midgely R, Harkin A, Bates G, Alexander L, Cassidy J (2011) Analysis of adverse events and quality of life data for an economic evaluation of adjuvant chemotherapy in colorectal cancer: when can we stop collecting? Trials 12(Suppl 1):A41PubMedCentralCrossRefGoogle Scholar
- 48.Stacey D, Légaré F, Col NF, Bennett CL, Barry MJ, Eden KB, Holmes-Rovner M, Llewellyn-Thomas H, Lyddiatt A, Thomson R (2014) Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 1 (1)Google Scholar
- 51.Mouradov D, Domingo E, Gibbs P, Jorissen RN, Li S, Soo PY, Lipton L, Desai J, Danielsen HE, Oukrif D (2013) Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations. Am J Gastroenterol 108:1785–1793CrossRefPubMedGoogle Scholar
- 53.Michaud D, Midthune D, Hermansen S, Leitzmann M, Harlan L, Kipnis V, Schatzkin A (2005) Comparison of cancer registry case ascertainment with SEER estimates and self-reporting in a subset of the NIT-AARP diet and health study. J Registry Manag 32(2):70–75Google Scholar